News Announcement：MARX Biotech Listed on the OTC Market on February 5th, Building a New OMO Retail Platform for the Health Industry
MARX Biotech (7731 TT), a new retail company in the big health market, made its debut on the OTC market on February 5th with an initial public offering price of NT$6.5 per share. On its first trading day, the stock price surged to a high of NT$21.15, closing at NT$17.6—an impressive increase of 170.77%.
Leading with innovation strategies and business model, MARX provides an omnichannel marketing system and an acceleration platform for various retail brands and products in the health field. In Q4 2023, MARX integrated several new brands, achieving significant industry synergies. December revenue surged 565.52% year-on-year to NT$54.05 million, accounting for nearly 20% of its total annual revenue. MARX Biotech has established a scalable and profitable business model that covers product development, brand building, marketing strategy, sales channels, and market expansion. Looking ahead, the company plans to acquire 3-5 domestic and international brands annually and enter 1-2 new international markets each year.
Founded in May 2021, MARX has a paid-in capital of NT$124.5 million and 249 million issued shares, each with a par value of NT$0.5. The company specializes in the niche market within the health retail industry, offering innovative products to the unique needs of various customer segments, emphasizing differentiation, precise positioning, and a tangible experience for each product, setting itself apart in a competitive market. Currently, the company operates four distinctive brands that cater to a diverse customer base, including men, fitness enthusiasts, children, mature women and pet parents.
TAIZAKU：A premium men's health brand combining Japanese style and fashion.
Phargoods+：A health brand for fitness enthusiasts and children, curated by pharmacist.
inyouso：A skincare brand developed by NTU food scientists and NTNU nutritionists.
SnowIOU：A beauty and wellness brand designed for mature women.
MARX will remain committed to developing differentiated products for its current audiences while expanding its collaborations with domestic and international health brands. Through global pharmacy expansion, and cross-border sales channels, MARX will deepen its efforts across products, marketing, and channels. This will accelerate the growth of both existing and new brands, enhancing MARX market scale and competitiveness edge.
Leading with innovation strategies and business model, MARX provides an omnichannel marketing system and an acceleration platform for various retail brands and products in the health field. In Q4 2023, MARX integrated several new brands, achieving significant industry synergies. December revenue surged 565.52% year-on-year to NT$54.05 million, accounting for nearly 20% of its total annual revenue. MARX Biotech has established a scalable and profitable business model that covers product development, brand building, marketing strategy, sales channels, and market expansion. Looking ahead, the company plans to acquire 3-5 domestic and international brands annually and enter 1-2 new international markets each year.
Founded in May 2021, MARX has a paid-in capital of NT$124.5 million and 249 million issued shares, each with a par value of NT$0.5. The company specializes in the niche market within the health retail industry, offering innovative products to the unique needs of various customer segments, emphasizing differentiation, precise positioning, and a tangible experience for each product, setting itself apart in a competitive market. Currently, the company operates four distinctive brands that cater to a diverse customer base, including men, fitness enthusiasts, children, mature women and pet parents.
TAIZAKU：A premium men's health brand combining Japanese style and fashion.
Phargoods+：A health brand for fitness enthusiasts and children, curated by pharmacist.
inyouso：A skincare brand developed by NTU food scientists and NTNU nutritionists.
SnowIOU：A beauty and wellness brand designed for mature women.
MARX will remain committed to developing differentiated products for its current audiences while expanding its collaborations with domestic and international health brands. Through global pharmacy expansion, and cross-border sales channels, MARX will deepen its efforts across products, marketing, and channels. This will accelerate the growth of both existing and new brands, enhancing MARX market scale and competitiveness edge.